Journal
DRUG DESIGN DEVELOPMENT AND THERAPY
Volume 16, Issue -, Pages 685-715Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S354841
Keywords
SARS-CoV-2; drug repurposing; clinical trials; molnupiravir; paxlovid
Categories
Funding
- research center at Almaarefa University
Ask authors/readers for more resources
This article provides a comprehensive review of drug repurposing for COVID-19 and the latest available oral anti-SARS-CoV-2 medications, discussing clinical trials, combination therapies, novel methods, and future prospects.
The rising outbreak of SARS-CoV-2 continues to unfold all over the world. The development of novel effective antiviral drugs to fight against SARS-CoV-2 is a time cost. As a result, some specific FDA-approved drugs have already been repurposed and authorized for COVID-19 treatment. The repurposed drugs used were either antiviral or non-antiviral drugs. Accordingly, the present review thoroughly focuses on the repurposing efficacy of these drugs including clinical trials experienced, the combination therapies used, the novel methods followed for treatment, and their future perspective. Therefore, drug repurposing was regarded as an effective avenue for COVID-19 treatment. Recently, molnupiravir is a prodrug antiviral medication that was approved in the United Kingdom in November 2021 for the treatment of COVID-19. On the other hand, PF-07321332 is an oral antiviral drug developed by Pfizer. For the treatment of COVID-19, the PF-07321332/ritonavir combination medication is used in Phase III studies and was marketed as Paxlovid. Herein, we represented the almost history of combating COVID-19 from repurposing to the recently available oral antiSARS-CoV-2 candidates, as a new hope to end the current pandemic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available